J Gynecol Oncol.  2008 Dec;19(4):280-280. 10.3802/jgo.2008.19.4.280.

In reply

• Yoo SC
• Chang SJ

• KMID: 2173422
• DOI: http://doi.org/10.3802/jgo.2008.19.4.280

Abstract

No abstract available.

Reference

1. Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, Alberts DS. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol. 2006. 24:1454–1458.

2. Obeidat B, Latimer J, Crawford R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Invest. 2004. 57:153–156.

3. Menczer J, Chetrit A, Sadetzki S, Golan A, Levy T. Follow-up of ovarian and primary peritoneal carcinoma: The value of physical examination in patients with pretreatment elevated CA125 levels. Gynecol Oncol. 2006. 103:137–140.